Delve into the far-reaching implications of the recently announced negotiated drug list as Avalere experts provide insights and answers to pressing questions surrounding CMS's landmark decision on Part D drug pricing and its impact on manufacturers, patients, and the future healthcare landscape.
Avalere experts delve into the dynamic patient assistance program landscape, including copay accumulators and maximizers, alternative funding initiatives, and the repercussions of policy shifts such as the Inflation Reduction Act and state-level copay accumulator bans.
Avalere experts explore how key policy changes, such as the Risk Adjustment Data Validation final rule, Inflation Reduction Act, and Medicare Advantage payment shifts, are shaping the landscape for health plans.
Avalere's policy experts discuss the key provisions and potential impacts of the recent CMS proposed rule related to the Medicaid drug rebate program (MDRP.)
In the fifth installment of our Respiratory Syncytial Virus (RSV) prevention series, Avalere experts discuss updates to the RSV prevention landscape, including newly approved products and recent Advisory Committee on Immunization Practices (ACIP) meeting discussions.
Avalere experts discuss Congress’ ongoing consideration of pharmacy benefit manager (PBM) legislation.
Avalere experts discuss trends and advancements in the kidney disease space, including payment models, digital health interventions, and key considerations for manufacturers.
Avalere experts will explore the potential implications of the Inflation Reduction Act (IRA)’s Medicare drug price negotiation program guidance and discuss implementation strategies for the near- and long-term.
Ahead of the Asembia and ISPOR 2023 conferences, Avalere experts discuss the increasing importance of value and evidence strategies as part of Inflation Reduction Act (IRA) implementation planning.
Ahead of Asembia 2023, Avalere experts discuss how the IRA and other regulatory changes will impact patient access and affordability.
In our Outlook 2023 webinar, Avalere expert Michael Ciarametaro discussed how evidence generation requirements will differ under the Inflation Reduction Act (IRA.)
The Inflation Reduction Act (IRA) brings some of the biggest changes affecting the pharmaceutical industry in the last decade. Avalere expert Megan West discusses how these shifts will impact pharmaceutical organizations and how Avalere can support in developing strategies to mitigate risk and identify opportunities across the product lifecycle.
Avalere experts Amanda Napoles and Shelby Harrington share recommendations for shifting to patient-centered value during our 2023 Outlook webinar.
Avalere expert Maddi Davidson discussed key EOM methods changes that will impact practice decision making.
Avalere expert Rebecca Yip discussed plan and beneficiary responses to IRA policies during our 2023 Outlook webinar.
In this video, Manoj Pawar, Chief Medical Officer of Mutual of Omaha, joins Avalere experts to discuss their recent partnership on a project that sought to identify innovative ways to use data to inform payer/provider partnerships in the Medicare program.
Join Avalere experts Elizabeth Carpenter and Matt Kazan for a discussion on the 2022 midterm election results and what to watch for future healthcare legislation.
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.
